306968-21-8

Basic information

• Product Name: N-{2-[1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl]ethyl}-N'-phenyloxalamide
• Synonyms: N-{2-[1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl]ethyl}-N'-phenyloxalamide
• CAS NO: 306968-21-8
• Molecular Weight: 423.512
• Mol File: 306968-21-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-{2-[1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl]ethyl}-N'-phenyloxalamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-{2-[1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl]ethyl}-N'-phenyloxalamide(306968-21-8)
• EPA Substance Registry System: N-{2-[1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl]ethyl}-N'-phenyloxalamide(306968-21-8)

Safety Data

• Hazardous Substances Data: 306968-21-8(Hazardous Substances Data)

Upstream product

• 1457-85-8 Ethyl oxanilate 
• 194612-31-2 2-[1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl]-2-ethylamine 
• 1094-91-3 2-(toluene-4-sulfonyloxymethyl)-2,3-dihydro-benzo[1,4]dioxine 
• 194612-30-1 [1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl]acetonitrile 
• 78056-67-4 1-(phenylmethyl)-4-piperidineacetonitrile 

Downstream Products

• 306968-22-9 N-{2-[1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl]ethyl}-N'-phenylethane-1,2-diamine 

Relevant articles and documents

New substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with α2-adrenoceptor antagonist activity

The emergence of a novel theory concerning the role of noradrenaline in the progression and the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases has provided a new impetus toward the discovery of novel compounds acting at α2-adrenoceptors. A series of substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl derivatives bearing an amide, urea, or imidazolidinone moiety was studied. Some members of this series of compounds proved to be potent α2-adrenoceptor antagonists with good selectivity versus α1-adrenergic and D2-dopamine receptors. Particular emphasis is given to compound 33g which displays potent α2-adrenoceptor binding affinity in vitro and central effects in vivo following oral administration.